Q&A: Dupilumab improves eosinophilic esophagitis outcomes for up to 52 weeks

Adolescents and adults experienced sustained improvements in eosinophilic esophagitis outcomes with dupilumab for up to 52 weeks, according to research presented at Digestive Disease Week 2023 in Chicago.Patients experienced better histologic, symptomatic and endoscopic outcomes during Part C of the phase 3 LIBERTY-EoE-TREET study despite any previous swallowed topical corticosteroid (STC) use or inadequate response, intolerance or contraindications for STCs.Further, Parts A and B of the study showed that dupilumab (Dupixent, Sanofi Genzyme/Regeneron) was effective in improving eosinophilicRead More